Hungarian pharmaceutical company Egis achieved gross and net profits of5.58 billion forint ($31.7 million) in 1996, up 14% on the previous year. Operating profits totaled 4.97 billion forint, an increase of 23.2%, reports MTI Econews.
Sales in 1996 amounted to 24.69 billion forint, up 24.6%, and exports grew 25% to just over 11 billion forint. Turnover of packaged medicines last year was 20 billion forint, accounting for 82.3% of total sales, while turnover of active ingredients was 3.9 billion forint, or 16% of total sales. Revenues from nutritional supplements accounted for 1% of the total.
Of the packaged (ie finished) medicines turnover, cardiovascular drugs represented 48.5%, and respiratory products accounted for 14% of the total.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze